Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Guillaume Meynard
Observed names:
G Meynard,
G. Meynard
Institution:
Centre Hospitalier Universitaire de Besançon
Observed institutions:
Centre Hospitalier Universitaire de Besançon,
L'Hôpital Nord Franche-Comté,
Pathway Genomics (United States),
Université de Franche-Comté
ORCID:
0000-0002-0646-4055
Observed ORCID:
0000-0002-0646-4055
OpenAlex ID:
A5083248016
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)
2020
·
Astrid Lièvre
, Anthony Turpin
, et al.
·
European Journal of Cancer
·
175
PDF
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study
2022
·
Magali Rebucci-Peixoto
, Angélique Vienot
, et al.
·
Frontiers in Oncology
·
31
PDF
Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients
2021
·
Laura Mansi
, Laurie Spehner
, et al.
·
European Journal of Cancer
·
31
PDF
Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
2022
·
Quentin Jacquinot
, Nathalie Meneveau
, et al.
·
Frontiers in Cardiovascular Medicine
·
30
PDF
Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer
2019
·
F. Bazan
, E. Dobi
, et al.
·
BMC Cancer
·
21
PDF
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
2025
·
Florence Joly
, Alexandra Leary
, et al.
·
Nature Communications
·
15
PDF
Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption
2025
·
Morgane Lopez
, Laurie Spehner
, et al.
·
Breast Cancer Research
·
15
PDF
First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report
2017
·
Guillaume Meynard
, Laura Mansi
, et al.
·
Oncology Reports
·
15
PDF
A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study
2023
·
Chloé Drozd
, Elsa Curtit
, et al.
·
BMC Cancer
·
13
PDF
Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry
2022
·
Zohair Selmani
, Chloé Molimard
, et al.
·
Scientific Reports
·
10
PDF
Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis
2022
·
Loïc Chaigneau
, Marine Jary
, et al.
·
Oncology
·
8
PDF
Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity.
2023
·
Jean-Philippe Zurcher
, Morgan Goujon
, et al.
·
Journal of Clinical Oncology
·
7
PDF
Real-life study of BRCA genetic screening in metastatic breast cancer
2017
·
G. Meynard
, C. Villanueva
, et al.
·
Annals of Oncology
·
6
PDF
Défaut de réparation de l’ADN : nouvelle piste thérapeutique pour le cancer de prostate métastatique
2018
·
Yohann Loriot
, Guillaume Meynard
, et al.
·
Bulletin du Cancer
·
5
Humeral metastasis as the only recurrence of a 5-year resected gastrointestinal stromal tumor: a case report
2021
·
C. Braunstein
, F. Sirveaux
, et al.
·
Journal of Medical Case Reports
·
4
PDF
Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer
2018
·
E. Curtit
, F. Bazan
, et al.
·
Annals of Oncology
·
4
ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial
2026
·
Guillaume Beinse
, Valerie Taly
, et al.
·
Clinical Cancer Research
·
2
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial
2026
·
Félix Blanc-Durand
, Catherine Genestie
, et al.
·
Clinical Cancer Research
·
2
Postcancer rehabilitation: multidisciplinary exercise – programme organisation and feasibility
2024
·
Chloé Drozd
, Quentin Jacquinot
, et al.
·
BMJ Supportive & Palliative Care
·
2
PDF
Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors
2025
·
Justine Dutheil
, Victor Pereira
, et al.
·
Breast Cancer Research
·
1
PDF
Management of cancer treatment-related fatigue in advanced breast cancer patients: an expert committee’s opinion
2025
·
Stéphanie Bécourt
, Sophie Abadie-Lacourtoisie
, et al.
·
Frontiers in Oncology
·
1
PDF
660P Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study
2024
·
L. Mansi
, F. Ghiringhelli
, et al.
·
Annals of Oncology
·
1
PDF
Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer
2024
·
Antoine El Kaddissi
, Dewi Vernerey
, et al.
·
Clinical Breast Cancer
·
1
PDF
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial
2023
·
Laurie Spehner
, Emeline Orillard
, et al.
·
BMJ Oncology
·
1
PDF
Real-World Activity and Safety of Metronomic Cyclophosphamide in Advanced Soft-Tissue Sarcoma: The Multicenter MeRCY Study
2026
·
Clément Bolognini
, Antoine Falcoz
, et al.
·
Cancers
Show more works
View as search
Works count:
51
Citation count:
401
H-index:
10
I10-index:
10
Year
Topic
Type